GLP1R and type 2 diabetes mellitus: The GLP-1 Receptor Agonist Intervention for Poor Responders After Bariatric Surgery (GRAVITAS) randomized clinical trial13 undertaken in individuals with persistent or recurrent type 2 diabetes after metabolic surgery using the type 2 diabetes dose (1.8 mg) liraglutide, as an adjunct to a lifestyle intervention, showed improved glycemic control with a mean weight difference of −4.2 kg (95% CI, −6.8 to −1.4) after 26 weeks.